BioNTech SE (BNTX)vsVertex Pharmaceuticals Inc (VRTX)
BNTX
BioNTech SE
$88.08
-1.69%
HEALTHCARE · Cap: $21.87B
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 336% more annual revenue ($12.22B vs $2.81B). VRTX leads profitability with a 35.5% profit margin vs -44.6%. BNTX appears more attractively valued with a PEG of 0.05. VRTX earns a higher WallStSmart Score of 68/100 (B-).
BNTX
Avoid35
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+28.6%
Fair Value
$153.17
Current Price
$88.08
$65.09 discount
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Weak financial health signals
ROE of -6.7% — below average capital efficiency
Revenue declined 35.4%
Earnings declined 43.2%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : BNTX
The strongest argument for BNTX centers on PEG Ratio, Price/Book, Debt/Equity. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : BNTX
The primary concerns for BNTX are Piotroski F-Score, Return on Equity, Revenue Growth.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
BNTX profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
BNTX carries more volatility with a beta of 1.32 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 35/100), backed by strong 35.5% margins. BNTX offers better value entry with a 28.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioNTech SE
HEALTHCARE · BIOTECHNOLOGY · USA
BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The company is headquartered in Mainz, Germany.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?